Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04632589 · ClinicalTrials.gov registry record · Early Phase 1
Losartan for Improved Vascular Endothelial Function After Preeclampsia
A Early Phase 1 study, sponsored by Anna Stanhewicz, PhD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT04632589 is a Early Phase 1 study that has completed, run by Anna Stanhewicz, PhD. The registered enrollment target is 11 participants.
The verdict
NCT04632589, a Early Phase 1 study, has completed, sponsored by Anna Stanhewicz, PhD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage and to test whether taking a medication that blocks angiotensin II receptors (losartan) decrease these negative effects in women who have had preeclampsia. Identification of these mechanisms and treatment strategies may lead to better clinical management,of cardiovascular disease risk in these women. In this study we use the blood vessels in the skin as a representative vascular bed. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickle-sized area of the skin in women who have had preeclampsia. We make these measurements after the subjects take a placebo and after they take losartan (an angiotensin II receptor blocker) to test whether this treatment improves vascular function in these women. As a compliment to these measurements, we also draw blood from the subjects and isolate the inflammatory cells to test how sensitive their inflammatory responses are following the placebo and the losartan treatment.
Interventions
- DRUG Placebo
- DRUG Losartan Potassium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-11-22 |
| Est. Completion | 2025-03-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04632589
The ClinicalTrials.gov registry entry for NCT04632589 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04632589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04632589 about?
NCT04632589 is a clinical study titled "Losartan for Improved Vascular Endothelial Function After Preeclampsia". Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclampt...
What is the current status of trial NCT04632589?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2020-11-22. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT04632589?
The interventions under investigation include: Placebo (DRUG), Losartan Potassium (DRUG).
Who is sponsoring clinical trial NCT04632589?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.